Transmedics Group Inc

Research Transmedics Group Inc (TMDX) on Bullrun: valuation model: 75.8% undervalued, market cap USD 2.33B, P/E 15.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTMDX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal75.8% undervalued
• Market capUSD 2.33B
• P/E15.4
• Financial periodFY2025
• RevenueUSD 605.49M
• Revenue growth37.1%
• Net incomeUSD 190.30M
• Free cash flowUSD 133.59M
• Gross margin59.9%

Valuation Snapshot

Bullrun's latest valuation model marks Transmedics Group Inc as 75.8% undervalued; latest market cap is USD 2.33B; P/E is 15.4.

About Transmedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Frequently asked questions

Is Transmedics Group Inc overvalued or undervalued?

Bullrun's valuation model currently marks Transmedics Group Inc as 75.8% undervalued.

What is Transmedics Group Inc's market cap?

Transmedics Group Inc's market capitalization is USD 2.33B.

What is Transmedics Group Inc's P/E ratio?

Transmedics Group Inc's price-to-earnings (P/E) ratio is 15.4.

What does Transmedics Group Inc do?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.